Described herein are new silicone-based compounds that have short wavelength infrared (SWIR) absorption and emission. The silicone-based compounds are readily accessible and obtainable on large scale with high purity through simple purification procedures. In one aspect, the silicone-based compounds have an absorption extending into the SWIR region and an emission maximum in the SWIR region which is promising for biological imaging applications.

A compound includes a first linker having a first end connected to the carrier, a second linker having a first end connected to the carrier, a third linker having a first end connected to the carrier, a first fluorescent entity connected to a second end of the first linker, a second fluorescent entity different from the first fluorescent entity connected to a second end of the second linker, and a biomolecule connected to a second end of the third linker. The biomolecule is configured to connect to a biomarker. A method of detecting biomarkers is also disclosed.

The present invention provides compositions and methods for imaging tumor resections.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.

The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

In one aspect, methods of targeted nanoparticles and cell delivery are described herein. In some embodiments methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.

Gas vesicles, protein variants and related compositions methods and systems for singleplexed and/or multiplexed ultrasound imaging of a target site in which a gas vesicle provides contrast for the imaging which is modifiable by application of a selectable acoustic collapse pressure value of the gas vesicle.

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Uptake of hypoxia-sensitive PET tracers is dependent on tissue transport properties, specifically, distribution volume. Variability in tissue transport properties reduces the sensitivity of static PET imaging to hypoxia. When tissue transport (v.sub.d) effects are substantial, correlations between the two methods of determining hypoxic fractions are greatly reduced—that is, trapping rates k.sub.3 are only modestly correlated with tumour-to-blood ratio (TBR). In other words, the usefulness of dynamic- and static-PET based hypoxia surrogates, trapping rate k.sub.3 and TBR, in determining hypoxic fractions is reduced in regions where diffusive equilibrium is achieved slowly. A process is provided for quantifying hypoxic fractions using a novel biomarker for hypoxia, hypoxia-sensitive tracer binding rate k.sub.b, based on PET imaging data. The same formalism can be applied to model the kinetics of non-binding CT and MT contrast agents, giving histopathological information about the imaged tissue.